Literature DB >> 1783440

Pharmacological properties of cephalosporins.

W Christ1.   

Abstract

The cephalosporins differ in the substituents attached at the 3 and/or 7 positions of the molecule. Very schematically, substitution at C3 mainly modifies the overall pharmacokinetic properties whereas substitution at position 7 influences the antibacterial characteristics. When using the more common "generation" system for classification, three generations can be distinguished on the basis of their antibacterial spectrum, potency, and their stability to beta-lactamases. The first generation cephalosporins have similar antibacterial and pharmacokinetic characteristics. C3-esterified cephalosporins (e.g. cephalothin and cephapirin) are significantly metabolized. The so-called second generation cephalosporins exhibit only minor differences with respect to the pharmacokinetic properties in contrast to the third generation cephalosporins. The apparent volumes of distribution of most cephalosporins range between seven and 20 1, indicating that they mainly stay in the extracellular space. Plasma protein binding is variable from compound to compound. Generally, the major route of elimination of most cephalosporins is via the kidney except for cefoperazone and ceftriaxone which are both excreted to a large extent by the biliary route. With the exception of cefonicid, cefotetan and cefriaxone, which have longer elimination half-lives (i.e. 4.5, 3.5 and around eight hours), all other cephalosporins have a half-life ranging from 0.5 to 2.5 hours. The pattern of adverse reactions is comparable for all the cephalosporins although there are slight differences in both the incidence and the type of reactions. The major categories of adverse reactions are gastrointestinal, dermatologic, hypersensitivity, haematologic, hepatic, renal as well as CNS effects. Alcohol intolerance (antabus-like effect) can occur when cephalosporins containing the NMTT moiety are administered concomitantly.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783440     DOI: 10.1007/bf01645535

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  34 in total

1.  Cephaloridine, cephalothin and the kidney.

Authors:  R D Foord
Journal:  J Antimicrob Chemother       Date:  1975       Impact factor: 5.790

2.  Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.

Authors:  T Bergan
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

3.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

Review 4.  The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.

Authors:  H C Neu
Journal:  Annu Rev Pharmacol Toxicol       Date:  1982       Impact factor: 13.820

Review 5.  Third generation cephalosporins: safety profiles after 10 years of clinical use.

Authors:  H C Neu
Journal:  J Clin Pharmacol       Date:  1990-05       Impact factor: 3.126

Review 6.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

7.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin.

Authors:  B M Tune; D Fravert; C Y Hsu
Journal:  Biochem Pharmacol       Date:  1989-03-01       Impact factor: 5.858

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

View more
  7 in total

1.  Is There a Difference in Infection Risk Between Single and Multiple Doses of Prophylactic Antibiotics? A Meta-analysis.

Authors:  Sean P Ryan; Beau J Kildow; Timothy L Tan; Javad Parvizi; Michael P Bolognesi; Thorsten M Seyler
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

Review 2.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

3.  Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.

Authors:  C Sauve; E Azoulay-Dupuis; P Moine; C Darras-Joly; V Rieux; C Carbon; J P Bédos
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone.

Authors:  Hakan Alagozlu; Mehmet Cindoruk; Selahattin Unal
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 6.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

7.  Prevalence and clinical characteristics of antibiotics associated drug induced liver injury.

Authors:  Jin Hwa Park; Susie Hong; Dae Won Jun; Jai Hoon Yoon; Kang Nyeong Lee; Hang Lak Lee; Oh Young Lee; Byung Chul Yoon; Ho Soon Choi
Journal:  Ann Transl Med       Date:  2021-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.